Siga Technologies (SIGA) Other financing activities (2017 - 2018)
Siga Technologies' (SIGA) quarterly Other financing activities came in at $9200.0 in Q4 2018, down 85.16% on a YoY basis from $62001.0 in Q4 2017, and down 96.36% quarter-over-quarter from $252679.0 in Q3 2018.
Powered by 
Analysis
Siga Technologies (SIGA) Other financing activities (2017 - 2018) Analysis & Trends
Siga Technologies (SIGA) has reported Other financing activities for 2 consecutive years, with $9200.0 the latest figure, recorded in Q4 2018.
- For the quarter ending Q4 2018, Other financing activities fell 85.16% year-over-year to $9200.0; the trailing twelve-month figure through Dec 2019 stood at $323880.0 (changed 0.0% YoY), and the FY2018 full-year result was $261879.0, up 192.61% from the prior year.
- Other financing activities fell to $9200.0 in Q4 2018 per SIGA's latest filing, from $252679.0 in the prior quarter.
- Across five years, Other financing activities topped out at $252679.0 in Q3 2018 and bottomed at $9200.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Siga Technologies | 220.19 Mn | 65.22 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 9,200.00 |
| Sep 30, 2018 | 252,679.00 |
| Dec 31, 2017 | 62,001.00 |